All In Biotech

Drug Trial Radar · NCT05197270

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 215 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

215

Planned (sponsor's estimate)

Start

Dec 9, 2021

Primary completion

Mar 2027

Study completion Jan 2031

Sponsor

Lead sponsor
4D Molecular TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.

Conditions

  • Neovascular (Wet) Age-Related Macular Degeneration

Interventions

  • 4D-150 IVTBiological

    4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept

  • Aflibercept IVTBiological

    Commercially available Active Comparator Other Name: Eylea

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parametersTime frame: 52 weeks

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Barnet Delaney Perkins Eye Center

    Phoenix, Arizona · Recruiting

  • California Retina Consultants

    Oxnard, California · Recruiting

  • Retinal Consultants Medical Group

    Sacramento, California · Recruiting

  • Colorado Retina Associates

    Lakewood, Colorado · Recruiting

  • Rand Eye Institute

    Deerfield Beach, Florida · Suspended

  • Retina Group of Florida

    Fort Lauderdale, Florida · Recruiting

  • Retina Vitreous Consultants, LLP DBA Retina Group of Florida

    Fort Lauderdale, Florida · Active not recruiting

  • Vitreo Retinal Associates

    Gainesville, Florida · Recruiting

  • Florida Eye Associates

    Melbourne, Florida · Recruiting

  • Retinal Specialty Institute

    Pensacola, Florida · Recruiting

  • Retina Vitreous Associates of Florida

    Tampa, Florida · Recruiting

  • University Retina and Macula Associates

    Oak Forest, Illinois · Recruiting

  • Retina Partners Midwest

    Carmel, Indiana · Recruiting

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland · Recruiting

  • Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center

    Boston, Massachusetts · Recruiting

  • Sierra Eye Associates

    Reno, Nevada · Recruiting

  • Western Carolina Retinal Associates

    Asheville, North Carolina · Withdrawn

  • Verum Research, LLC

    Eugene, Oregon · Recruiting

  • Mid Atlantic Retina

    Bethlehem, Pennsylvania · Recruiting

  • Palmetto Retina Center, LLC

    West Columbia, South Carolina · Recruiting

  • Tennessee Retina

    Nashville, Tennessee · Recruiting

  • Austin Clinical Research

    Austin, Texas · Recruiting

  • Valley Retina Institute, PA

    McAllen, Texas · Recruiting

  • Retina Consultants of Texas

    The Woodlands, Texas · Withdrawn

  • Pacific Northwest Retina LLC

    Bellevue, Washington · Withdrawn

  • Emanuelli Research and Development Center, LLC

    Arecibo, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.